Established in 2011, Innovent Biologics is a biotechnology company that develops, manufactures and commercialises medicine for oncology, cardiovascular and metabolic diseases, autoimmune diseases and ophthalmology. The Suzhou-headquartered company was listed on the Hong Kong stock exchange on October 31, 2018.